Drug Profile


Alternative Names: Naproxen/esomeprazole; naproxen/esomeprazole magnesium; PN-400; Vimovo

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca; POZEN
  • Developer Aralez Pharmaceuticals Inc.; AstraZeneca
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 20 Aug 2015 Horizon Pharma receives patent allowance for esomeprazole/naproxen in USA
  • 04 Feb 2015 POZEN and Horizon Pharma obtain additional patent protection for esomeprazole/naproxen in USA
  • 18 Nov 2014 Efficacy data from two phase III trials in Osteoarthritis presented at the 78th American College of Rheumatology and the 49th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top